ofloxacin has been researched along with Tuberculosis in 79 studies
Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.
9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.
ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.
Tuberculosis: Any of the infectious diseases of man and other animals caused by species of MYCOBACTERIUM TUBERCULOSIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Assess the activities of levofloxacin (LVLX) against Mycobacterium tuberculosis both in vitro and in vivo, the pharmacokinetics of LVLX and the effectiveness and safety of it in the treatment of pulmonary tuberculosis, with ofloxacin(OFLX) as control." | 9.09 | [Antituberculosis effect of levofloxacin]. ( Duan, L; Lu, Y; Zhu, L, 2000) |
| "To characterize the susceptibility to levofloxacin of clinical isolates of Mycobacterium tuberculosis (MTB) obtained from patients with HIV-related tuberculosis and to characterize the molecular genetics of levofloxacin resistance." | 9.08 | Susceptibility to levofloxacin of Myocobacterium tuberculosis isolates from patients with HIV-related tuberculosis and characterization of a strain with levofloxacin monoresistance. Community Programs for Clinical Research on AIDS 019 and the AIDS Clinica ( Chirgwin, K; El Sadr, WM; Hafner, R; Heifets, LB; Klein, O; Kreiswirth, BN; Matts, JP; Musser, JM; Nelson, ET; Perlman, DC; Salomon, N; Telzak, EE, 1997) |
| "The aim of this work was to characterize novel palladium (Pd) complexes with second-line antitubercular drugs, namely capreomycin (C), kanamycin (K) and ofloxacin (Ofx), and to address the in vitro extracellular and intracellular activity against Mycobacterium tuberculosis infection." | 7.80 | Synthesis, characterization and in vitro extracellular and intracellular activity against Mycobacterium tuberculosis infection of new second-line antitubercular drug-palladium complexes. ( Blasi, P; Giovagnoli, S; Marenzoni, ML; Nocchetti, M; Ricci, M; Santi, C; Schoubben, A, 2014) |
| "It has been shown previously that fluoroquinolone resistance (defined by resistance to at least 2 mg/liter ofloxacin) has a different impact on moxifloxacin monotherapy depending on the mutation in the sole fluoroquinolone target in Mycobacterium tuberculosis, i." | 7.79 | Impact of fluoroquinolone resistance on bactericidal and sterilizing activity of a moxifloxacin-containing regimen in murine tuberculosis. ( Aubry, A; Brossier, F; Chauffour, A; Fillion, A; Jarlier, V; Veziris, N, 2013) |
| "This study aimed to analyze the association of mutation patterns in gyrA and gyrB genes and the ofloxacin resistance levels in clinical Mycobacterium tuberculosis isolates sampled in 2009 from East China." | 7.77 | Association of mutation patterns in gyrA/B genes and ofloxacin resistance levels in Mycobacterium tuberculosis isolates from East China in 2009. ( Cui, Z; Hu, Z; Huang, X; Lu, J; Wang, J, 2011) |
| "The purpose of this study was to evaluate tuberculosis treatment including levofloxacin (LVFX) and to investigate the effectiveness of changing drug regimens at our hospital." | 7.77 | [Evaluation of tuberculosis treatment including levofloxacin (LVFX) in cases who could not continue standard regimen]. ( Akagawa, S; Ariga, H; Kaneko, Y; Kawabe, Y; Kawashima, M; Kunogi, M; Machida, K; Masuda, K; Matsui, H; Matsui, Y; Nagai, H; Nagayama, N; Nakajima, Y; Ohshima, N; Shimada, M; Suzuki, J; Tamura, A; Toyota, E, 2011) |
| "Seventy-four Mycobacterium tuberculosis clinical isolates from China were subjected to drug susceptibility testing using ethambutol, isoniazid, rifampin, and ofloxacin." | 7.74 | Lack of correlation between embB mutation and ethambutol MIC in Mycobacterium tuberculosis clinical isolates from China. ( Otomo, K; Shi, R; Sugawara, I; Zhang, G; Zhang, J, 2007) |
| "A high rate of double point mutations in gyrA (56% of 87 ofloxacin-resistant Mycobacterium tuberculosis clinical isolates) indicates the emergence of fluoroquinolone resistance." | 7.73 | Emergence of ofloxacin resistance in Mycobacterium tuberculosis clinical isolates from China as determined by gyrA mutation analysis using denaturing high-pressure liquid chromatography and DNA sequencing. ( Kazumi, Y; Li, C; Shi, R; Sugawara, I; Zhang, J, 2006) |
| "To determine the long-term tolerability of prophylactic administration of pyrazinamide and levofloxacin in patients possibly exposed to multidrug-resistant tuberculosis (MDRTB) after undergoing solid organ transplantation." | 7.71 | Limited tolerability of levofloxacin and pyrazinamide for multidrug-resistant tuberculosis prophylaxis in a solid organ transplant population. ( Lou, HX; McKaveney, TP; Shullo, MA, 2002) |
| "The authors report a case of severe BCG hepatitis resistant to tuberculostatic therapy and treated with ofloxacin." | 7.71 | [Can ofloxacin constitute an alternative antitubercular treatment for BCG hepatitis?]. ( Debois, H; Fendler, JP; Kepenekian, G; Mége, JL, 2002) |
| "Twenty patients with urinary tuberculosis were treated with ofloxacin (200 mg/day, 6 months), rifampin (600 mg/day, 3 months) and isoniazid (300 mg/day, 3 months) between 1989 and 1990." | 7.71 | Bacteriological conversion in twenty urinary tuberculosis patients treated with ofloxacin, rifampin and isoniazid: a 10-year follow-up study. ( Castiñeiras, AA; Della-Latta, P; Herreras, A; Pérez-Pascual, P; Zarranz, JE, 2002) |
| "The in vitro activity of moxifloxacin, gatifloxacin, levofloxacin and linezolid was evaluated against 234 strains of Mycobacterium tuberculosis isolated in the Southeast of Spain." | 7.71 | In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis. ( López, M; Rodríguez, JC; Royo, G; Ruiz, M, 2002) |
| "The antimicrobial activities of levofloxacin, clarithromycin and KRM-1648 against Mycobacterium tuberculosis (MTB) and Mycobacterium avium complex (MAC) residing in Mono Mac 6 human macrophage-like cells (MM6-Mphis) and A-549 human type II alveolar epithelial cells (A-549 cells) were studied." | 7.70 | Antimicrobial activities of levofloxacin, clarithromycin, and KRM-1648 against Mycobacterium tuberculosis and Mycobacterium avium complex replicating within Mono Mac 6 human macrophage and A-549 type II alveolar cell lines. ( Akaki, T; Kawahara, S; Sato, K; Tomioka, H, 2000) |
| "In tests with 18 drug-susceptible strains of Mycobacterium tuberculosis, the MIC at which 50% of the strains are inhibited by levofloxacin (LVFX) was one dilution less than that at which 50% of the strains are inhibited by ofloxacin (OFLO), but the MICs at which 90% of the strains are inhibited were similar." | 7.69 | In vitro and in vivo activities of levofloxacin against Mycobacterium tuberculosis. ( Grosset, J; JI, B; Lounis, N; Truffot-Pernot, C, 1995) |
| "Enoxacin (ENX) showed a moderate degree of activities in vitro against Mycobacterium tuberculosis in modified Saunton medium and modified Lowenstein-Jensen Medium with MICs from 1 to 8micrograms/ml." | 7.69 | [Comparison of in-vitro and in-vivo activities of enoxacin and ofloxacin against the Mycobacterium tuberculosis]. ( Li, H; Liu, S; Xu, G, 1995) |
| "After 3 days of treatment with ofloxacin (300 mg given orally once daily), the drug levels in serum and pleural fluid 2 and 4 h after drug administration in patients with tuberculous pleural effusion were assessed by a rapid high-performance liquid chromatography assay." | 7.68 | Ofloxacin penetration into tuberculous pleural effusion. ( Chan, CY; Cheung, SW; Kwan, SY; Lee, J; Wong, PC; Yew, WW, 1991) |
| "A new antibacterial substance, ofloxacin (DL8280), was used in the treatment of pulmonary tuberculosis." | 7.67 | Therapeutic effect of a new antibacterial substance ofloxacin (DL8280) on pulmonary tuberculosis. ( Amano, H; Nakamura, E; Tsukamura, M; Yoshii, S, 1985) |
| "Ofloxacin MIC was determined by resazurin microtitre assay (REMA) and the effects on MICs of efflux pump inhibitors (CCCP, reserpine and verapamil) were determined." | 5.43 | A novel resistance mutation in eccC5 of the ESX-5 secretion system confers ofloxacin resistance in Mycobacterium tuberculosis. ( Blackman, A; Eilertson, B; Guo, Y; Herrera, M; Maruri, F; Shyr, Y; Sterling, TR; van der Heijden, Y, 2016) |
| "tuberculosis were consecutively selected from routine Tuberculosis laboratory." | 5.42 | Prevalence of gyrA and B gene mutations in fluoroquinolone-resistant and -sensitive clinical isolates of Mycobacterium tuberculosis and their relationship with MIC of ofloxacin. ( Dixit, P; Jain, A; Jaiswal, I; Prakash, S; Singh, M; Singh, P; Venkatesh, V, 2015) |
| "Moxifloxacin was effective against mutant strain GyrB D500N, with the lowest MIC (0." | 5.36 | Should moxifloxacin be used for the treatment of extensively drug-resistant tuberculosis? An answer from a murine model. ( Aubry, A; Chauffour, A; Farinotti, R; Fernandez, C; Jarlier, V; Lott, MC; Poissy, J; Veziris, N, 2010) |
| "Members of the fluoroquinolone class are being actively evaluated for inclusion in tuberculosis chemotherapy regimens, and we sought to determine the best in vitro and pharmacodynamic predictors of in vivo efficacy in mice." | 5.34 | Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy. ( Balasubramanian, V; Bharath, S; Gaonkar, S; Jayaram, R; Jayashree, R; Kaur, P; Mahesh, BN; Nandi, V; Shandil, RK; Suresh, BL, 2007) |
| "Concomitant use of a levofloxacin-containing regimen resulted in a similar rate of adverse events compared with conventional first-line regimens when used for treatment of active TB, despite a history of adverse events." | 5.33 | Levofloxacin treatment of active tuberculosis and the risk of adverse events. ( Elwood, RK; FitzGerald, JM; Marra, CA; Marra, F; Moadebi, S; Shi, P; Stark, G, 2005) |
| "tuberculosis are reported." | 5.28 | In vitro and in vivo activities of sparfloxacin (AT-4140) against Mycobacterium tuberculosis. ( Grosset, J; Ji, B; Truffot-Pernot, C, 1991) |
| "Assess the activities of levofloxacin (LVLX) against Mycobacterium tuberculosis both in vitro and in vivo, the pharmacokinetics of LVLX and the effectiveness and safety of it in the treatment of pulmonary tuberculosis, with ofloxacin(OFLX) as control." | 5.09 | [Antituberculosis effect of levofloxacin]. ( Duan, L; Lu, Y; Zhu, L, 2000) |
| "To characterize the susceptibility to levofloxacin of clinical isolates of Mycobacterium tuberculosis (MTB) obtained from patients with HIV-related tuberculosis and to characterize the molecular genetics of levofloxacin resistance." | 5.08 | Susceptibility to levofloxacin of Myocobacterium tuberculosis isolates from patients with HIV-related tuberculosis and characterization of a strain with levofloxacin monoresistance. Community Programs for Clinical Research on AIDS 019 and the AIDS Clinica ( Chirgwin, K; El Sadr, WM; Hafner, R; Heifets, LB; Klein, O; Kreiswirth, BN; Matts, JP; Musser, JM; Nelson, ET; Perlman, DC; Salomon, N; Telzak, EE, 1997) |
| "276 rifampin-resistance tuberculosis (RR-TB) and 30 rifampicin-sensitive clinical isolates were randomly selected from patients with tuberculosis in Shanghai Pulmonary Hospital (SPH)." | 3.96 | Use of whole-genome sequencing to predict Mycobacterium tuberculosis drug resistance in Shanghai, China. ( Gao, R; Guo, Y; Shen, X; Tan, G; Wang, H; Wu, X; Wu, Z; Yang, J; Yu, F, 2020) |
| "To evaluate performance of thin layer agar (TLA) 7H11 method for detection of ofloxacin (OFX) and kanamycin (KM) resistance in smear positive clinical specimens of patients with tuberculosis comparing the results with gold standard MGIT 960 system." | 3.91 | Evaluation of Thin Layer Agar 7H11 for Direct Susceptibility Testing of Mycobacterium Tuberculosis Complex against Second Line Anti Tuberculosis Drugs on Smear Positive Specimens. ( Gardezi, AH; Hussain, A; Ikram, A; Khadim, MT; Satti, L; Zaman, G, 2019) |
| "Ofloxacin and moxifloxacin are the most commonly used fluoroquinolones (FQs) for the treatment of tuberculosis." | 3.85 | Double mutation in DNA gyrase confers moxifloxacin resistance and decreased fitness of Mycobacterium smegmatis. ( Bao, L; Luo, T; Mi, Y; Peng, X; Sun, C; Wang, C; Yang, G; Yuan, J; Zhang, C, 2017) |
| "The aim of this work was to characterize novel palladium (Pd) complexes with second-line antitubercular drugs, namely capreomycin (C), kanamycin (K) and ofloxacin (Ofx), and to address the in vitro extracellular and intracellular activity against Mycobacterium tuberculosis infection." | 3.80 | Synthesis, characterization and in vitro extracellular and intracellular activity against Mycobacterium tuberculosis infection of new second-line antitubercular drug-palladium complexes. ( Blasi, P; Giovagnoli, S; Marenzoni, ML; Nocchetti, M; Ricci, M; Santi, C; Schoubben, A, 2014) |
| "It has been shown previously that fluoroquinolone resistance (defined by resistance to at least 2 mg/liter ofloxacin) has a different impact on moxifloxacin monotherapy depending on the mutation in the sole fluoroquinolone target in Mycobacterium tuberculosis, i." | 3.79 | Impact of fluoroquinolone resistance on bactericidal and sterilizing activity of a moxifloxacin-containing regimen in murine tuberculosis. ( Aubry, A; Brossier, F; Chauffour, A; Fillion, A; Jarlier, V; Veziris, N, 2013) |
| "Our data confirm the usefulness of moxifloxacin in the treatment of tuberculosis and suggest that levofloxacin may be used as an alternative drug in the treatment of latent tuberculosis when it is not possible to use isoniazid." | 3.77 | Comparison of the bactericidal activity of various fluoroquinolones against Mycobacterium tuberculosis in an in vitro experimental model. ( Cremades, R; Galiana, A; García-Pachón, E; López, P; Rodríguez, JC; Royo, G; Ruiz-García, M, 2011) |
| "The purpose of this study was to evaluate tuberculosis treatment including levofloxacin (LVFX) and to investigate the effectiveness of changing drug regimens at our hospital." | 3.77 | [Evaluation of tuberculosis treatment including levofloxacin (LVFX) in cases who could not continue standard regimen]. ( Akagawa, S; Ariga, H; Kaneko, Y; Kawabe, Y; Kawashima, M; Kunogi, M; Machida, K; Masuda, K; Matsui, H; Matsui, Y; Nagai, H; Nagayama, N; Nakajima, Y; Ohshima, N; Shimada, M; Suzuki, J; Tamura, A; Toyota, E, 2011) |
| "This study aimed to analyze the association of mutation patterns in gyrA and gyrB genes and the ofloxacin resistance levels in clinical Mycobacterium tuberculosis isolates sampled in 2009 from East China." | 3.77 | Association of mutation patterns in gyrA/B genes and ofloxacin resistance levels in Mycobacterium tuberculosis isolates from East China in 2009. ( Cui, Z; Hu, Z; Huang, X; Lu, J; Wang, J, 2011) |
| "Fluoroquinolones are not indicated for use for the treatment of pneumonia in children; however, non-levofloxacin-susceptible Streptococcus pneumoniae (NLSSP) has emerged in South Africa among children receiving treatment for multidrug-resistant tuberculosis." | 3.75 | Molecular characterization of emerging non-levofloxacin-susceptible pneumococci isolated from children in South Africa. ( de Gouveia, L; du Plessis, M; Klugman, KP; von Gottberg, A; Wolter, N, 2009) |
| "Seventy-four Mycobacterium tuberculosis clinical isolates from China were subjected to drug susceptibility testing using ethambutol, isoniazid, rifampin, and ofloxacin." | 3.74 | Lack of correlation between embB mutation and ethambutol MIC in Mycobacterium tuberculosis clinical isolates from China. ( Otomo, K; Shi, R; Sugawara, I; Zhang, G; Zhang, J, 2007) |
| "A high rate of double point mutations in gyrA (56% of 87 ofloxacin-resistant Mycobacterium tuberculosis clinical isolates) indicates the emergence of fluoroquinolone resistance." | 3.73 | Emergence of ofloxacin resistance in Mycobacterium tuberculosis clinical isolates from China as determined by gyrA mutation analysis using denaturing high-pressure liquid chromatography and DNA sequencing. ( Kazumi, Y; Li, C; Shi, R; Sugawara, I; Zhang, J, 2006) |
| "The authors report a case of severe BCG hepatitis resistant to tuberculostatic therapy and treated with ofloxacin." | 3.71 | [Can ofloxacin constitute an alternative antitubercular treatment for BCG hepatitis?]. ( Debois, H; Fendler, JP; Kepenekian, G; Mége, JL, 2002) |
| "To determine the long-term tolerability of prophylactic administration of pyrazinamide and levofloxacin in patients possibly exposed to multidrug-resistant tuberculosis (MDRTB) after undergoing solid organ transplantation." | 3.71 | Limited tolerability of levofloxacin and pyrazinamide for multidrug-resistant tuberculosis prophylaxis in a solid organ transplant population. ( Lou, HX; McKaveney, TP; Shullo, MA, 2002) |
| "After clinical illness, treatment, and death of a captive male bongo antelope (Tragelaphus eurycerus isaaci) caused by tuberculosis involving Mycobacterium bovis, four tuberculin test reactive captive bongos were treated for 6 mo with isoniazid (INH) and rifampin (RIF) and intermittent single doses of other medications before being euthanized." | 3.71 | Population pharmacokinetics of antituberculous drugs and treatment of Mycobacterium bovis infection in bongo antelope (Tragelaphus eurycerus isaaci). ( Aguilar, R; Auclair, B; Maslow, JN; Mikota, SK; Peloquin, CA, 2002) |
| "The in vitro activity of moxifloxacin, gatifloxacin, levofloxacin and linezolid was evaluated against 234 strains of Mycobacterium tuberculosis isolated in the Southeast of Spain." | 3.71 | In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis. ( López, M; Rodríguez, JC; Royo, G; Ruiz, M, 2002) |
| "Twenty patients with urinary tuberculosis were treated with ofloxacin (200 mg/day, 6 months), rifampin (600 mg/day, 3 months) and isoniazid (300 mg/day, 3 months) between 1989 and 1990." | 3.71 | Bacteriological conversion in twenty urinary tuberculosis patients treated with ofloxacin, rifampin and isoniazid: a 10-year follow-up study. ( Castiñeiras, AA; Della-Latta, P; Herreras, A; Pérez-Pascual, P; Zarranz, JE, 2002) |
| "The antimicrobial activities of levofloxacin, clarithromycin and KRM-1648 against Mycobacterium tuberculosis (MTB) and Mycobacterium avium complex (MAC) residing in Mono Mac 6 human macrophage-like cells (MM6-Mphis) and A-549 human type II alveolar epithelial cells (A-549 cells) were studied." | 3.70 | Antimicrobial activities of levofloxacin, clarithromycin, and KRM-1648 against Mycobacterium tuberculosis and Mycobacterium avium complex replicating within Mono Mac 6 human macrophage and A-549 type II alveolar cell lines. ( Akaki, T; Kawahara, S; Sato, K; Tomioka, H, 2000) |
| "In tests with 18 drug-susceptible strains of Mycobacterium tuberculosis, the MIC at which 50% of the strains are inhibited by levofloxacin (LVFX) was one dilution less than that at which 50% of the strains are inhibited by ofloxacin (OFLO), but the MICs at which 90% of the strains are inhibited were similar." | 3.69 | In vitro and in vivo activities of levofloxacin against Mycobacterium tuberculosis. ( Grosset, J; JI, B; Lounis, N; Truffot-Pernot, C, 1995) |
| "Enoxacin (ENX) showed a moderate degree of activities in vitro against Mycobacterium tuberculosis in modified Saunton medium and modified Lowenstein-Jensen Medium with MICs from 1 to 8micrograms/ml." | 3.69 | [Comparison of in-vitro and in-vivo activities of enoxacin and ofloxacin against the Mycobacterium tuberculosis]. ( Li, H; Liu, S; Xu, G, 1995) |
| "Mice with experimental tuberculosis were given isoniazid, rifampicin, erythromycin, cefotaxime, ofloxacin." | 3.69 | [Immunotropic activity of antimicrobial agents used in tuberculosis]. ( Aleksandrova, AE; Vinogradova, TI, 1996) |
| "After 3 days of treatment with ofloxacin (300 mg given orally once daily), the drug levels in serum and pleural fluid 2 and 4 h after drug administration in patients with tuberculous pleural effusion were assessed by a rapid high-performance liquid chromatography assay." | 3.68 | Ofloxacin penetration into tuberculous pleural effusion. ( Chan, CY; Cheung, SW; Kwan, SY; Lee, J; Wong, PC; Yew, WW, 1991) |
| "The minimal inhibitory concentrations for 90% of strains (MIC90) of ofloxacin against Mycobacterium tuberculosis and Mycobacterium xenopi was 2 mg/l." | 3.68 | Activities of pefloxacin and ofloxacin against mycobacteria: in vitro and mouse experiments. ( Grosset, J; Ji, B; Truffot-Pernot, C, 1991) |
| "A new antibacterial substance, ofloxacin (DL8280), was used in the treatment of pulmonary tuberculosis." | 3.67 | Therapeutic effect of a new antibacterial substance ofloxacin (DL8280) on pulmonary tuberculosis. ( Amano, H; Nakamura, E; Tsukamura, M; Yoshii, S, 1985) |
| "The series is part of an ongoing randomised controlled trial assessing rechallenge dosing following TB-associated cutaneous ADR." | 2.77 | Multiple drug hypersensitivity reactions to anti-tuberculosis drugs: five cases in HIV-infected patients. ( Dheda, K; Lehloenya, RJ; Todd, G; Wallace, J, 2012) |
| "Ofloxacin MIC was determined by resazurin microtitre assay (REMA) and the effects on MICs of efflux pump inhibitors (CCCP, reserpine and verapamil) were determined." | 1.43 | A novel resistance mutation in eccC5 of the ESX-5 secretion system confers ofloxacin resistance in Mycobacterium tuberculosis. ( Blackman, A; Eilertson, B; Guo, Y; Herrera, M; Maruri, F; Shyr, Y; Sterling, TR; van der Heijden, Y, 2016) |
| "tuberculosis were consecutively selected from routine Tuberculosis laboratory." | 1.42 | Prevalence of gyrA and B gene mutations in fluoroquinolone-resistant and -sensitive clinical isolates of Mycobacterium tuberculosis and their relationship with MIC of ofloxacin. ( Dixit, P; Jain, A; Jaiswal, I; Prakash, S; Singh, M; Singh, P; Venkatesh, V, 2015) |
| "tuberculosis were obtained from the Novosibirsk Research Institute of Tuberculosis, Russia." | 1.40 | Characterization of extensively drug-resistant Mycobacterium tuberculosis isolates circulating in Siberia. ( Alkhovik, OI; Cherednichenko, AG; Dymova, MA; Filipenko, ML; Khrapov, EA; Petrenko, TI, 2014) |
| "Ciprofloxacin and ofloxacin were classified as older-generation fluoroquinolones; levofloxacin, moxifloxacin and gatifloxacin were considered newer agents." | 1.39 | Fluoroquinolone susceptibility in Mycobacterium tuberculosis after pre-diagnosis exposure to older- versus newer-generation fluoroquinolones. ( Bian, A; Blackman, A; Eden, S; Maruri, F; Mitchel, E; Shintani, AK; Sterling, TR; van der Heijden, YF; Warkentin, JV, 2013) |
| "Moxifloxacin was effective against mutant strain GyrB D500N, with the lowest MIC (0." | 1.36 | Should moxifloxacin be used for the treatment of extensively drug-resistant tuberculosis? An answer from a murine model. ( Aubry, A; Chauffour, A; Farinotti, R; Fernandez, C; Jarlier, V; Lott, MC; Poissy, J; Veziris, N, 2010) |
| "Tuberculosis is a public health problem worldwide." | 1.35 | Sternal tuberculosis. ( Howell, JM; Mohammadi, A, 2009) |
| "Members of the fluoroquinolone class are being actively evaluated for inclusion in tuberculosis chemotherapy regimens, and we sought to determine the best in vitro and pharmacodynamic predictors of in vivo efficacy in mice." | 1.34 | Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy. ( Balasubramanian, V; Bharath, S; Gaonkar, S; Jayaram, R; Jayashree, R; Kaur, P; Mahesh, BN; Nandi, V; Shandil, RK; Suresh, BL, 2007) |
| "Concomitant use of a levofloxacin-containing regimen resulted in a similar rate of adverse events compared with conventional first-line regimens when used for treatment of active TB, despite a history of adverse events." | 1.33 | Levofloxacin treatment of active tuberculosis and the risk of adverse events. ( Elwood, RK; FitzGerald, JM; Marra, CA; Marra, F; Moadebi, S; Shi, P; Stark, G, 2005) |
| "Because increased hepatotoxicity was observed with first line antituberculous agents using four drug standard induction therapy in orthotopic liver transplant patients, we evaluated the efficacy and adverse effects of a novel continuation regimen for the treatment of tuberculosis in orthotopic liver transplant patients at a University Hospital in New York City." | 1.31 | Tuberculosis in orthotopic liver transplant patients: increased toxicity of recommended agents; cure of disseminated infection with nonconventional regimens. ( Emre, S; Meyers, BR; Miller, C; Papanicolaou, GA; Sheiner, P, 2000) |
| "tuberculosis are about the same." | 1.30 | [Experimental study on the antituberculous activity of ofloxacins]. ( Duan, L; Li, H; Liang, G, 1997) |
| "tuberculosis are reported." | 1.28 | In vitro and in vivo activities of sparfloxacin (AT-4140) against Mycobacterium tuberculosis. ( Grosset, J; Ji, B; Truffot-Pernot, C, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (3.80) | 18.7374 |
| 1990's | 14 (17.72) | 18.2507 |
| 2000's | 27 (34.18) | 29.6817 |
| 2010's | 32 (40.51) | 24.3611 |
| 2020's | 3 (3.80) | 2.80 |
| Authors | Studies |
|---|---|
| Shandil, RK | 1 |
| Jayaram, R | 1 |
| Kaur, P | 1 |
| Gaonkar, S | 1 |
| Suresh, BL | 1 |
| Mahesh, BN | 1 |
| Jayashree, R | 1 |
| Nandi, V | 1 |
| Bharath, S | 1 |
| Balasubramanian, V | 1 |
| García, A | 1 |
| Bocanegra-García, V | 1 |
| Palma-Nicolás, JP | 1 |
| Rivera, G | 1 |
| Pedgaonkar, GS | 2 |
| Sridevi, JP | 2 |
| Jeankumar, VU | 2 |
| Saxena, S | 2 |
| Devi, PB | 2 |
| Renuka, J | 2 |
| Yogeeswari, P | 2 |
| Sriram, D | 2 |
| Saharan, VD | 1 |
| Mahajan, SS | 1 |
| Fan, YL | 1 |
| Wu, JB | 1 |
| Cheng, XW | 1 |
| Zhang, FZ | 1 |
| Feng, LS | 1 |
| Girase, PS | 1 |
| Dhawan, S | 1 |
| Kumar, V | 1 |
| Shinde, SR | 1 |
| Palkar, MB | 1 |
| Karpoormath, R | 1 |
| Wu, X | 1 |
| Gao, R | 1 |
| Shen, X | 1 |
| Guo, Y | 2 |
| Yang, J | 1 |
| Wu, Z | 1 |
| Tan, G | 1 |
| Wang, H | 1 |
| Yu, F | 1 |
| Winckler, JL | 1 |
| Draper, HR | 1 |
| Schaaf, HS | 1 |
| van der Laan, LE | 1 |
| Hesseling, AC | 1 |
| Garcia-Prats, AJ | 1 |
| Luo, T | 1 |
| Yuan, J | 1 |
| Peng, X | 1 |
| Yang, G | 1 |
| Mi, Y | 1 |
| Sun, C | 1 |
| Wang, C | 1 |
| Zhang, C | 1 |
| Bao, L | 1 |
| Gupta, A | 1 |
| Pal, SK | 1 |
| Pandey, D | 1 |
| Fakir, NA | 1 |
| Rathod, S | 1 |
| Sinha, D | 1 |
| SivaKumar, S | 1 |
| Sinha, P | 1 |
| Periera, M | 1 |
| Balgam, S | 1 |
| Sekar, G | 1 |
| UmaDevi, KR | 1 |
| Anupurba, S | 1 |
| Nema, V | 1 |
| Hussain, A | 1 |
| Zaman, G | 1 |
| Satti, L | 1 |
| Ikram, A | 1 |
| Gardezi, AH | 1 |
| Khadim, MT | 1 |
| Ahmad, Z | 1 |
| Tyagi, S | 1 |
| Minkowski, A | 1 |
| Peloquin, CA | 2 |
| Grosset, JH | 1 |
| Nuermberger, EL | 1 |
| van der Heijden, YF | 1 |
| Maruri, F | 2 |
| Blackman, A | 2 |
| Mitchel, E | 2 |
| Bian, A | 1 |
| Shintani, AK | 1 |
| Eden, S | 1 |
| Warkentin, JV | 1 |
| Sterling, TR | 4 |
| Chang, KC | 1 |
| Dheda, K | 2 |
| Fillion, A | 1 |
| Aubry, A | 4 |
| Brossier, F | 3 |
| Chauffour, A | 3 |
| Jarlier, V | 3 |
| Veziris, N | 4 |
| Ramachandran, G | 1 |
| Chandrasekaran, V | 1 |
| Hemanth Kumar, AK | 1 |
| Dewan, P | 1 |
| Swaminathan, S | 1 |
| Thomas, A | 1 |
| Jiang, GL | 2 |
| Chen, X | 1 |
| Song, Y | 2 |
| Zhao, Y | 2 |
| Huang, H | 2 |
| Kam, KM | 1 |
| Giovagnoli, S | 1 |
| Marenzoni, ML | 1 |
| Nocchetti, M | 1 |
| Santi, C | 1 |
| Blasi, P | 1 |
| Schoubben, A | 1 |
| Ricci, M | 1 |
| Singh, P | 1 |
| Jain, A | 1 |
| Dixit, P | 1 |
| Prakash, S | 1 |
| Jaiswal, I | 1 |
| Venkatesh, V | 1 |
| Singh, M | 1 |
| Dymova, MA | 1 |
| Cherednichenko, AG | 1 |
| Alkhovik, OI | 1 |
| Khrapov, EA | 1 |
| Petrenko, TI | 1 |
| Filipenko, ML | 1 |
| Yu, X | 1 |
| Ma, YF | 1 |
| Chen, ST | 1 |
| Wang, GR | 1 |
| Huang, HR | 1 |
| Eilertson, B | 1 |
| Herrera, M | 1 |
| van der Heijden, Y | 1 |
| Shyr, Y | 1 |
| Bernard, C | 1 |
| Robert, J | 1 |
| Hwang, SM | 1 |
| Kim, DD | 1 |
| Chung, SJ | 1 |
| Shim, CK | 1 |
| Wolter, N | 1 |
| du Plessis, M | 1 |
| von Gottberg, A | 1 |
| de Gouveia, L | 1 |
| Klugman, KP | 1 |
| Ho, CC | 1 |
| Chen, YC | 1 |
| Hu, FC | 1 |
| Yu, CJ | 1 |
| Yang, PC | 1 |
| Luh, KT | 1 |
| Lin, SY | 1 |
| Desmond, E | 1 |
| Bonato, D | 1 |
| Gross, W | 1 |
| Siddiqi, S | 1 |
| Caminero, JA | 1 |
| Sotgiu, G | 1 |
| Zumla, A | 1 |
| Migliori, GB | 1 |
| Poissy, J | 1 |
| Fernandez, C | 1 |
| Lott, MC | 1 |
| Farinotti, R | 1 |
| Cui, Z | 1 |
| Wang, J | 1 |
| Lu, J | 2 |
| Huang, X | 1 |
| Hu, Z | 1 |
| Cremades, R | 1 |
| Rodríguez, JC | 2 |
| García-Pachón, E | 1 |
| Galiana, A | 1 |
| Ruiz-García, M | 1 |
| López, P | 1 |
| Royo, G | 2 |
| Kunogi, M | 1 |
| Kawabe, Y | 1 |
| Suzuki, J | 1 |
| Shimada, M | 1 |
| Kaneko, Y | 1 |
| Matsui, Y | 1 |
| Kawashima, M | 1 |
| Ohshima, N | 1 |
| Ariga, H | 1 |
| Masuda, K | 1 |
| Matsui, H | 1 |
| Tamura, A | 1 |
| Nagai, H | 1 |
| Akagawa, S | 1 |
| Nagayama, N | 1 |
| Toyota, E | 1 |
| Machida, K | 1 |
| Nakajima, Y | 1 |
| Pantel, A | 1 |
| Petrella, S | 1 |
| Bastian, S | 1 |
| Mayer, C | 1 |
| Sokolova, GB | 1 |
| Maliev, BM | 1 |
| Mozhokina, GN | 1 |
| Elistratova, NA | 1 |
| Solov'eva, IP | 1 |
| Bugaenko, SE | 1 |
| Long, Q | 1 |
| Li, W | 1 |
| Du, Q | 1 |
| Fu, Y | 1 |
| Liang, Q | 1 |
| Xie, J | 1 |
| Lehloenya, RJ | 1 |
| Wallace, J | 1 |
| Todd, G | 1 |
| Keren, I | 1 |
| Mulcahy, LR | 1 |
| Lewis, K | 1 |
| Pang, Y | 1 |
| Wang, Y | 1 |
| Wang, S | 1 |
| Durek, C | 1 |
| Jurczok, A | 1 |
| Werner, H | 1 |
| Jocham, D | 1 |
| Bohle, A | 1 |
| Castiñeiras, AA | 1 |
| Pérez-Pascual, P | 1 |
| Zarranz, JE | 1 |
| Della-Latta, P | 1 |
| Herreras, A | 1 |
| Ruiz, M | 1 |
| López, M | 1 |
| Auclair, B | 1 |
| Mikota, SK | 1 |
| Aguilar, R | 1 |
| Maslow, JN | 1 |
| Ginsburg, AS | 1 |
| Woolwine, SC | 1 |
| Hooper, N | 1 |
| Benjamin, WH | 1 |
| Bishai, WR | 1 |
| Dorman, SE | 1 |
| Cheng, AF | 1 |
| Yew, WW | 2 |
| Chan, EW | 1 |
| Chin, ML | 1 |
| Hui, MM | 1 |
| Chan, RC | 1 |
| Biswas, SK | 1 |
| Bhusal, Y | 1 |
| Shiohira, CM | 1 |
| Yamane, N | 1 |
| Marra, F | 1 |
| Marra, CA | 1 |
| Moadebi, S | 1 |
| Shi, P | 1 |
| Elwood, RK | 1 |
| Stark, G | 1 |
| FitzGerald, JM | 1 |
| Shi, R | 2 |
| Zhang, J | 2 |
| Li, C | 1 |
| Kazumi, Y | 1 |
| Sugawara, I | 2 |
| Lourenço, MC | 1 |
| Junior, IN | 1 |
| De Souza, MV | 1 |
| Otomo, K | 1 |
| Zhang, G | 1 |
| Mohammadi, A | 1 |
| Howell, JM | 1 |
| Gaba, PD | 1 |
| Haley, C | 1 |
| Griffin, MR | 1 |
| Warkentin, J | 1 |
| Holt, E | 1 |
| Baggett, P | 1 |
| JI, B | 3 |
| Lounis, N | 1 |
| Truffot-Pernot, C | 3 |
| Grosset, J | 3 |
| Xu, G | 1 |
| Li, H | 2 |
| Liu, S | 1 |
| Aleksandrova, AE | 1 |
| Vinogradova, TI | 1 |
| Bermudez, LE | 1 |
| Kolonoski, P | 1 |
| Young, LS | 1 |
| Akaki, T | 3 |
| Sato, K | 3 |
| Shimizu, T | 1 |
| Tomioka, H | 3 |
| Kawahara, S | 2 |
| Perlman, DC | 1 |
| El Sadr, WM | 1 |
| Heifets, LB | 1 |
| Nelson, ET | 1 |
| Matts, JP | 1 |
| Chirgwin, K | 1 |
| Salomon, N | 1 |
| Telzak, EE | 1 |
| Klein, O | 1 |
| Kreiswirth, BN | 1 |
| Musser, JM | 1 |
| Hafner, R | 1 |
| Padełskaya, EN | 1 |
| Duan, L | 2 |
| Liang, G | 1 |
| Vacher, S | 1 |
| Pellegrin, JL | 1 |
| Leblanc, F | 1 |
| Fourche, J | 1 |
| Maugein, J | 1 |
| Meyers, BR | 1 |
| Papanicolaou, GA | 1 |
| Sheiner, P | 1 |
| Emre, S | 1 |
| Miller, C | 1 |
| Sirgel, F | 1 |
| Venter, A | 1 |
| Mitchison, D | 1 |
| Bowersox, J | 1 |
| Lu, Y | 1 |
| Zhu, L | 1 |
| Lou, HX | 1 |
| Shullo, MA | 1 |
| McKaveney, TP | 1 |
| Richter, E | 1 |
| Wessling, J | 1 |
| Lügering, N | 1 |
| Domschke, W | 1 |
| Rüsch-Gerdes, S | 1 |
| Fendler, JP | 1 |
| Debois, H | 1 |
| Mége, JL | 1 |
| Kepenekian, G | 1 |
| Lee, J | 1 |
| Chan, CY | 1 |
| Cheung, SW | 1 |
| Wong, PC | 1 |
| Kwan, SY | 1 |
| Tsukamura, M | 3 |
| Nakamura, E | 1 |
| Yoshii, S | 1 |
| Amano, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy of Clarithromycin or Moxifloxacin Containing Regimen in 6 Months Sputum Conversion of Mycobacterium Xenopi[NCT01298336] | Phase 3 | 92 participants (Actual) | Interventional | 2011-03-02 | Completed | ||
| The Treatment of Pulmonary Mycobacterium Tuberculosis in HIV Infection[NCT00001033] | Phase 3 | 650 participants | Interventional | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 reviews available for ofloxacin and Tuberculosis
| Article | Year |
|---|---|
Recent advances in antitubercular natural products.
Topics: Animals; Antitubercular Agents; Biological Products; Drug Resistance, Multiple, Bacterial; Genes, Ba | 2012 |
Fluoroquinolone derivatives and their anti-tubercular activities.
Topics: Animals; Antitubercular Agents; Dose-Response Relationship, Drug; Fluoroquinolones; Humans; Molecula | 2018 |
An appraisal of anti-mycobacterial activity with structure-activity relationship of piperazine and its analogues: A review.
Topics: Animals; Antitubercular Agents; Drug Design; Drug Discovery; Humans; Mycobacterium tuberculosis; Pip | 2021 |
Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis.
Topics: Amikacin; Antitubercular Agents; Capreomycin; Drug Resistance, Multiple; Ethambutol; Extensively Dru | 2010 |
Levofloxacin.
Topics: Animals; Antitubercular Agents; Humans; Levofloxacin; Ofloxacin; Treatment Outcome; Tuberculosis | 2008 |
[Ofloxacin in mycobacteriosis therapy].
Topics: Animals; Anti-Infective Agents; Clinical Trials as Topic; Disease Models, Animal; Humans; Leprosy, T | 1997 |
3 trials available for ofloxacin and Tuberculosis
| Article | Year |
|---|---|
Multiple drug hypersensitivity reactions to anti-tuberculosis drugs: five cases in HIV-infected patients.
Topics: Adult; Antitubercular Agents; Coinfection; Drug Eruptions; Drug Hypersensitivity; Edema; Eosinophili | 2012 |
Susceptibility to levofloxacin of Myocobacterium tuberculosis isolates from patients with HIV-related tuberculosis and characterization of a strain with levofloxacin monoresistance. Community Programs for Clinical Research on AIDS 019 and the AIDS Clinica
Topics: AIDS-Related Opportunistic Infections; Anti-Infective Agents; Antibiotics, Antitubercular; Antituber | 1997 |
[Antituberculosis effect of levofloxacin].
Topics: Adolescent; Adult; Aged; Animals; Antitubercular Agents; Humans; Levofloxacin; Male; Mice; Microbial | 2000 |
70 other studies available for ofloxacin and Tuberculosis
| Article | Year |
|---|---|
Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy.
Topics: Animals; Anti-Bacterial Agents; Antitubercular Agents; Aza Compounds; Ciprofloxacin; Dose-Response R | 2007 |
Development of 2-(4-oxoquinazolin-3(4H)-yl)acetamide derivatives as novel enoyl-acyl carrier protein reductase (InhA) inhibitors for the treatment of tuberculosis.
Topics: Acetamides; Animals; Bacterial Proteins; Cell Line; Cell Survival; Dose-Response Relationship, Drug; | 2014 |
Development of benzo[d]oxazol-2(3H)-ones derivatives as novel inhibitors of Mycobacterium tuberculosis InhA.
Topics: Animals; Antitubercular Agents; Bacterial Proteins; Benzoxazoles; Cell Line; Humans; Mice; Microbial | 2014 |
Development of gallic acid formazans as novel enoyl acyl carrier protein reductase inhibitors for the treatment of tuberculosis.
Topics: Animals; Anti-Bacterial Agents; Antitubercular Agents; Bacterial Proteins; Binding Sites; Catalytic | 2017 |
Use of whole-genome sequencing to predict Mycobacterium tuberculosis drug resistance in Shanghai, China.
Topics: Adult; Amikacin; Antitubercular Agents; China; Drug Resistance, Bacterial; Ethambutol; Humans; Isoni | 2020 |
Acceptability of levofloxacin, moxifloxacin and linezolid among children and adolescents treated for TB.
Topics: Adolescent; Anti-Bacterial Agents; Aza Compounds; Child; Fluoroquinolones; Humans; Levofloxacin; Lin | 2020 |
Double mutation in DNA gyrase confers moxifloxacin resistance and decreased fitness of Mycobacterium smegmatis.
Topics: DNA Gyrase; Drug Resistance, Bacterial; Fluoroquinolones; Genetic Fitness; Genomics; Humans; Microbi | 2017 |
PknB remains an essential and a conserved target for drug development in susceptible and MDR strains of M. Tuberculosis.
Topics: Antitubercular Agents; Base Sequence; DNA, Bacterial; Drug Resistance, Multiple, Bacterial; Ethambut | 2017 |
Evaluation of Thin Layer Agar 7H11 for Direct Susceptibility Testing of Mycobacterium Tuberculosis Complex against Second Line Anti Tuberculosis Drugs on Smear Positive Specimens.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antitubercular Agents; Bacteriolo | 2019 |
Contribution of moxifloxacin or levofloxacin in second-line regimens with or without continuation of pyrazinamide in murine tuberculosis.
Topics: Analysis of Variance; Animals; Anti-Bacterial Agents; Antitubercular Agents; Aza Compounds; Disease | 2013 |
Fluoroquinolone susceptibility in Mycobacterium tuberculosis after pre-diagnosis exposure to older- versus newer-generation fluoroquinolones.
Topics: Adult; Aged; Anti-Bacterial Agents; Aza Compounds; Case-Control Studies; Ciprofloxacin; DNA Gyrase; | 2013 |
Rationalizing use of fluoroquinolones and pyrazinamide in the battle against multidrug-resistant tuberculosis.
Topics: Animals; Anti-Bacterial Agents; Antitubercular Agents; Aza Compounds; Female; Fluoroquinolones; Moxi | 2013 |
Impact of fluoroquinolone resistance on bactericidal and sterilizing activity of a moxifloxacin-containing regimen in murine tuberculosis.
Topics: Amikacin; Animals; Antitubercular Agents; Aza Compounds; DNA Gyrase; Drug Administration Schedule; D | 2013 |
Estimation of content of anti-TB drugs supplied at centres of the Revised National TB Control Programme in Tamil Nadu, India.
Topics: Antitubercular Agents; Cycloserine; Drug Stability; Drug Storage; Drug Therapy, Combination; Ethambu | 2013 |
First proficiency testing of second-line anti-tuberculosis drug susceptibility testing in 12 provinces of China.
Topics: Amikacin; Antitubercular Agents; Capreomycin; China; Drug Resistance, Bacterial; Humans; Kanamycin; | 2013 |
Synthesis, characterization and in vitro extracellular and intracellular activity against Mycobacterium tuberculosis infection of new second-line antitubercular drug-palladium complexes.
Topics: Antitubercular Agents; Capreomycin; Kanamycin; Microbial Sensitivity Tests; Mycobacterium tuberculos | 2014 |
Prevalence of gyrA and B gene mutations in fluoroquinolone-resistant and -sensitive clinical isolates of Mycobacterium tuberculosis and their relationship with MIC of ofloxacin.
Topics: Antitubercular Agents; Base Sequence; Codon; DNA Gyrase; Drug Resistance, Bacterial; Drug Resistance | 2015 |
Characterization of extensively drug-resistant Mycobacterium tuberculosis isolates circulating in Siberia.
Topics: Adult; Amikacin; Antitubercular Agents; Capreomycin; Cross-Sectional Studies; Drug Resistance, Multi | 2014 |
Sensititre® MYCOTB MIC plate for drug susceptibility testing of Mycobacterium tuberculosis complex isolates.
Topics: Amikacin; Aminosalicylic Acid; Antitubercular Agents; China; Cycloserine; Ethambutol; Humans; Isonia | 2016 |
A novel resistance mutation in eccC5 of the ESX-5 secretion system confers ofloxacin resistance in Mycobacterium tuberculosis.
Topics: Antitubercular Agents; Bacterial Proteins; Bacterial Secretion Systems; Case-Control Studies; DNA Mu | 2016 |
In vivo Mycobacterium tuberculosis fluoroquinolone resistance emergence: a complex phenomenon poorly detected by current diagnostic tests.
Topics: Animals; Antitubercular Agents; Disease Models, Animal; Drug Resistance, Bacterial; Female; Fluoroqu | 2016 |
Delivery of ofloxacin to the lung and alveolar macrophages via hyaluronan microspheres for the treatment of tuberculosis.
Topics: Administration, Inhalation; Administration, Oral; Aerosols; Animals; Anti-Bacterial Agents; Cell Lin | 2008 |
Molecular characterization of emerging non-levofloxacin-susceptible pneumococci isolated from children in South Africa.
Topics: Adolescent; Anti-Bacterial Agents; Bacterial Proteins; Bacterial Typing Techniques; Carrier State; C | 2009 |
Safety of fluoroquinolone use in patients with hepatotoxicity induced by anti-tuberculosis regimens.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alanine Transaminase; Anti-Bacterial Agents; Antitubercu | 2009 |
Multicenter evaluation of Bactec MGIT 960 system for second-line drug susceptibility testing of Mycobacterium tuberculosis complex.
Topics: Amikacin; Antitubercular Agents; Capreomycin; Ethionamide; Humans; Levofloxacin; Microbial Sensitivi | 2009 |
Should moxifloxacin be used for the treatment of extensively drug-resistant tuberculosis? An answer from a murine model.
Topics: Animals; Antitubercular Agents; Aza Compounds; DNA Gyrase; Enoxacin; Fluoroquinolones; Gatifloxacin; | 2010 |
Association of mutation patterns in gyrA/B genes and ofloxacin resistance levels in Mycobacterium tuberculosis isolates from East China in 2009.
Topics: Antitubercular Agents; China; DNA Gyrase; DNA Mutational Analysis; DNA, Bacterial; Drug Resistance, | 2011 |
Comparison of the bactericidal activity of various fluoroquinolones against Mycobacterium tuberculosis in an in vitro experimental model.
Topics: Antitubercular Agents; Aza Compounds; Ciprofloxacin; Drug Resistance, Bacterial; Fluoroquinolones; H | 2011 |
[Evaluation of tuberculosis treatment including levofloxacin (LVFX) in cases who could not continue standard regimen].
Topics: Aged; Anti-Bacterial Agents; Antitubercular Agents; Drug Administration Schedule; Drug Resistance, B | 2011 |
Extending the definition of the GyrB quinolone resistance-determining region in Mycobacterium tuberculosis DNA gyrase for assessing fluoroquinolone resistance in M. tuberculosis.
Topics: Anti-Bacterial Agents; DNA Gyrase; DNA, Bacterial; DNA, Superhelical; Drug Resistance, Bacterial; Fe | 2012 |
[Efficacy and tolerance of rezonizate in complex with fluoroquinolones or mycobutin on a model of experimental murine tuberculosis].
Topics: Animals; Antibiotics, Antitubercular; Disease Models, Animal; Drug Therapy, Combination; Drug Tolera | 2011 |
gyrA/B fluoroquinolone resistance allele profiles amongst Mycobacterium tuberculosis isolates from mainland China.
Topics: Alleles; China; DNA Gyrase; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Levofloxacin; Micr | 2012 |
Persister eradication: lessons from the world of natural products.
Topics: Anti-Bacterial Agents; Biofilms; Biological Products; Drug Resistance, Multiple, Bacterial; Humans; | 2012 |
Study of the rifampin monoresistance mechanism in Mycobacterium tuberculosis.
Topics: Antitubercular Agents; Bacterial Proteins; Base Sequence; Biological Transport; DNA-Directed RNA Pol | 2013 |
[The outcome of a survey on the use of levofloxacin for the treatment of tuberculosis].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Child; Data Collection; Female; H | 2012 |
Optimal treatment of systemic bacillus Calmette-Guérin infection: investigations in an animal model.
Topics: Animals; Cell Survival; Ciprofloxacin; Disease Models, Animal; Dose-Response Relationship, Drug; Dru | 2002 |
Bacteriological conversion in twenty urinary tuberculosis patients treated with ofloxacin, rifampin and isoniazid: a 10-year follow-up study.
Topics: Adult; Aged; Anti-Infective Agents, Urinary; Antitubercular Agents; Drug Therapy, Combination; Femal | 2002 |
In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis.
Topics: Acetamides; Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Drug Resistanc | 2002 |
Population pharmacokinetics of antituberculous drugs and treatment of Mycobacterium bovis infection in bongo antelope (Tragelaphus eurycerus isaaci).
Topics: Amikacin; Animals; Antelopes; Antitubercular Agents; Area Under Curve; Ethambutol; Female; Isoniazid | 2002 |
The rapid development of fluoroquinolone resistance in M. tuberculosis.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Infective Agents; Ciprofloxacin; Drug Resistance, | 2003 |
Multiplex PCR amplimer conformation analysis for rapid detection of gyrA mutations in fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates.
Topics: Anti-Infective Agents; DNA Gyrase; DNA Primers; DNA, Bacterial; Drug Resistance, Bacterial; Fluoroqu | 2004 |
Chemotherapy of leprosy.
Topics: Anti-Bacterial Agents; Clofazimine; Dapsone; Dose-Response Relationship, Drug; Drug Combinations; Dr | 2004 |
Determination of in vitro synergy when three antimicrobial agents are combined against Mycobacterium tuberculosis.
Topics: Anti-Bacterial Agents; Antibiotics, Antitubercular; Antitubercular Agents; Ciprofloxacin; Clarithrom | 2005 |
Levofloxacin treatment of active tuberculosis and the risk of adverse events.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibiotics, Antitubercular; Antitubercular Agents; Case | 2005 |
Emergence of ofloxacin resistance in Mycobacterium tuberculosis clinical isolates from China as determined by gyrA mutation analysis using denaturing high-pressure liquid chromatography and DNA sequencing.
Topics: Anti-Bacterial Agents; China; Chromatography, High Pressure Liquid; DNA Gyrase; DNA Mutational Analy | 2006 |
In vitro activity of ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and gatifloxacin against multidrug-resistant Mycobacterium tuberculosis in Rio de Janeiro Brazil.
Topics: AIDS-Related Opportunistic Infections; Brazil; Drug Resistance, Microbial; Drug Resistance, Multiple | 2007 |
Lack of correlation between embB mutation and ethambutol MIC in Mycobacterium tuberculosis clinical isolates from China.
Topics: Antitubercular Agents; Bacterial Proteins; China; Drug Resistance, Bacterial; Ethambutol; Humans; Is | 2007 |
Sternal tuberculosis.
Topics: Abscess; Adult; Anti-Bacterial Agents; Antitubercular Agents; Drug Therapy, Combination; Humans; Mal | 2009 |
Increasing outpatient fluoroquinolone exposure before tuberculosis diagnosis and impact on culture-negative disease.
Topics: Adult; Aged; Ciprofloxacin; Female; Fluoroquinolones; Humans; Logistic Models; Male; Middle Aged; Mu | 2007 |
In vitro and in vivo activities of levofloxacin against Mycobacterium tuberculosis.
Topics: Animals; Anti-Infective Agents; Antitubercular Agents; Dose-Response Relationship, Drug; Female; Flu | 1995 |
[Comparison of in-vitro and in-vivo activities of enoxacin and ofloxacin against the Mycobacterium tuberculosis].
Topics: Animals; Antitubercular Agents; Enoxacin; Female; Male; Mice; Microbial Sensitivity Tests; Mycobacte | 1995 |
[Immunotropic activity of antimicrobial agents used in tuberculosis].
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antitubercular Agents; Cefotaxime; Cephalospo | 1996 |
Roxithromycin alone and in combination with either ethambutol or levofloxacin for disseminated Mycobacterium avium infections in beige mice.
Topics: Animals; Anti-Bacterial Agents; Antitubercular Agents; Bacteremia; Colony Count, Microbial; Drug Com | 1996 |
[In vivo activities of benzoxazinorifamycin KRM-1648, clarithromycin, and levofloxacin, or combination of KRM-1648 with diclofenac sodium against Mycobacterium avium infection induced in mice].
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti | 1997 |
Antimicrobial activities of benzoxazinorifamycin KRM-1648, clarithromycin and levofloxacin against intracellular Mycobacterium avium complex phagocytosed by murine peritoneal macrophages.
Topics: Animals; Anti-Bacterial Agents; Clarithromycin; Female; Levofloxacin; Lung; Macrophages, Peritoneal; | 1998 |
[Experimental study on the antituberculous activity of ofloxacins].
Topics: Animals; Anti-Infective Agents; Antitubercular Agents; Ethambutol; Female; Male; Mice; Mycobacterium | 1997 |
Comparative antimycobacterial activities of ofloxacin, ciprofloxacin and grepafloxacin.
Topics: Anti-Infective Agents; Ciprofloxacin; Colony Count, Microbial; Fluoroquinolones; Humans; Macrophages | 1999 |
Tuberculosis in orthotopic liver transplant patients: increased toxicity of recommended agents; cure of disseminated infection with nonconventional regimens.
Topics: Adult; Aged; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Therapy, Combinatio | 2000 |
Sources of variation in studies of the early bactericidal activity of antituberculosis drugs.
Topics: Anti-Infective Agents; Antitubercular Agents; Hong Kong; Humans; Isoniazid; Microbial Sensitivity Te | 2001 |
Antimicrobial activities of levofloxacin, clarithromycin, and KRM-1648 against Mycobacterium tuberculosis and Mycobacterium avium complex replicating within Mono Mac 6 human macrophage and A-549 type II alveolar cell lines.
Topics: Anti-Bacterial Agents; Cell Line; Clarithromycin; Epithelial Cells; Humans; Levofloxacin; Macrophage | 2000 |
CPCRA researchers present OI studies at Vancouver.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Anti-Infective Agents; Antifung | 1996 |
Limited tolerability of levofloxacin and pyrazinamide for multidrug-resistant tuberculosis prophylaxis in a solid organ transplant population.
Topics: Anti-Infective Agents; Antitubercular Agents; Drug Resistance, Microbial; Drug Resistance, Multiple; | 2002 |
Mycobacterium avium subsp. paratuberculosis infection in a patient with HIV, Germany.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Infective Agents; Antitubercular Agents; Ciproflo | 2002 |
[Can ofloxacin constitute an alternative antitubercular treatment for BCG hepatitis?].
Topics: Aged; Anti-Infective Agents; Antitubercular Agents; Hepatitis; Humans; Male; Microbial Sensitivity T | 2002 |
In vitro and in vivo activities of sparfloxacin (AT-4140) against Mycobacterium tuberculosis.
Topics: Animals; Anti-Infective Agents; Dose-Response Relationship, Drug; Female; Fluoroquinolones; Mice; Mi | 1991 |
Ofloxacin penetration into tuberculous pleural effusion.
Topics: Adult; Chromatography, High Pressure Liquid; Female; Humans; Male; Middle Aged; Mycobacterium tuberc | 1991 |
Activities of pefloxacin and ofloxacin against mycobacteria: in vitro and mouse experiments.
Topics: Animals; Female; Mice; Mycobacterium tuberculosis; Nontuberculous Mycobacteria; Ofloxacin; Pefloxaci | 1991 |
[Therapeutic effect of ofloxacin on mice challenged by ofloxacin-resistant Mycobacterium bovis strains].
Topics: Animals; Anti-Bacterial Agents; Drug Resistance, Microbial; Mice; Mycobacterium bovis; Ofloxacin; Ox | 1987 |
Therapeutic effect of a new antibacterial substance ofloxacin (DL8280) on pulmonary tuberculosis.
Topics: Adult; Aged; Drug Resistance, Microbial; Female; Humans; Male; Middle Aged; Ofloxacin; Oxazines; Tub | 1985 |
Antituberculosis activity of ofloxacin (DL 8280) on experimental tuberculosis in mice.
Topics: Animals; Antitubercular Agents; Drug Evaluation, Preclinical; Liver; Mice; Mice, Inbred Strains; Myc | 1985 |